
    
      This was a Phase 2a multicenter, open-label, single arm, combination treatment study of a
      regimen of ABT-450/r/ABT-072, and ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-(1a
      or 1b) infected treatment-na√Øve participants.
    
  